US2022395482A1PendingUtilityA1

Glycogen or polysaccharide storage disease treatment method

82
Assignee: BAYLOR RES INSTITUTEPriority: Jul 2, 2004Filed: Apr 22, 2022Published: Dec 15, 2022
Est. expiryJul 2, 2024(expired)· nominal 20-yr term from priority
Inventors:Charles R. Roe
A61K 31/19A23K 20/158A61K 9/0095A23V 2002/00A61K 31/225A23K 50/10A23L 33/115A61P 3/00A61K 9/0053A23L 33/12A61K 38/47A61K 31/202C12Y 302/0102A23K 20/174A61K 31/20A61K 31/23A23K 50/80A23K 50/75A23L 33/10A61K 31/22A23L 33/175A23L 2/52A23L 33/16
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a fatty acid oxidation disorder (FOD) in a subject in need thereof, wherein the method comprises administering to the subject a composition comprising an active agent, wherein the active agent consists essentially of a triheptanoin, and wherein the composition has an acid value of 0.1 or less mg KOH per gram and a hydroxyl value of 2.8 or less mg KOH per gram. 
     
     
         2 . The method of  claim 1 , wherein the composition is administered in a range of 1 to 4 grams of triheptanoin per kilogram body weight per day. 
     
     
         3 . The method of  claim 1 , wherein the composition is administered in a range of 0.1 to 2 grams of triheptanoin per kilogram body weight per day. 
     
     
         4 . The method of  claim 1 , wherein the composition is in a dosage unit, wherein the dosage unit comprises at least 15 grams of the triheptanoin. 
     
     
         5 . The method of  claim 4 , wherein the dosage unit comprises 15 to 75 grams of the triheptanoin. 
     
     
         6 . The method of  claim 1 , wherein the composition is provided in an amount that provides 15% to 40% of the daily dietary calories of the subject. 
     
     
         7 . The method of  claim 1 , wherein the composition is provided in an amount that provides 20% to 35% of the daily dietary calories of the subject. 
     
     
         8 . The method of  claim 1 , wherein the composition is provided in an amount that provides 25% to 35% of the daily dietary calories of the subject. 
     
     
         9 . The method of  claim 1 , wherein the composition is provided as a nutritional supplement. 
     
     
         10 . The method of  claim 1 , wherein the composition is provided as a dietary formulation. 
     
     
         11 . The method of  claim 1 , wherein the composition is a pharmaceutical composition. 
     
     
         12 . The method of  claim 1 , wherein the composition is administered parenterally. 
     
     
         13 . The method of  claim 1 , wherein the composition is administered enterally. 
     
     
         14 . The method of  claim 1 , wherein the composition is administered orally. 
     
     
         15 . The method of  claim 1 , wherein the FOD is selected from carnitine palmitoyl transferase I (CPT I) deficiency, carnitine-acylcarnitine translocase (CACT) deficiency, carnitine palmitoyl transferase I (CPT II) deficiency, very long chain acyl-CoA dehydrogenase (VLCAD) deficiency, trifunctional protein (TFP) deficiency, long chain acyl 3-hydroxy CoA dehydrogenase (LCHAD) deficiency and short chain acyl CoA dehydrogenase (SCAD) deficiency. 
     
     
         16 . The method of  claim 14 , wherein the FOD is CPT II deficiency. 
     
     
         17 . The method of  claim 11 , wherein the FOD is VLCAD deficiency. 
     
     
         18 . The method of  claim 14 , wherein the FOD is LCHAD deficiency. 
     
     
         19 . The method of  claim 14 , wherein the FOD is TFP deficiency. 
     
     
         20 . The method of  claim 14 , wherein the FOD is CACT deficiency.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.